Wells Fargo & Company Oncolytics Biotech Inc Transaction History

Wells Fargo & Company

  • $407 Billion
  • Q2 2024

A detailed history of Wells Fargo & Company transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Wells Fargo & Company holds 4,401 shares of ONCY stock, worth $3,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,401
Previous 4,401 -0.0%
Holding current value
$3,916
Previous $4,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
SELL
$0.89 - $1.36 $234 - $357
-263 Reduced 5.64%
4,401 $4,000
Q4 2023

Feb 09, 2024
SELL
$1.22 - $2.09 $1,875 - $3,212
-1,537 Reduced 24.79%
4,664 $6,000
Q2 2023

Aug 15, 2023
BUY
$1.11 - $2.74 $1,000 - $2,468
901 Added 17.0%
6,201 $16,000
Q1 2023

May 12, 2023
BUY
$1.2 - $1.91 $2,160 - $3,438
1,800 Added 51.43%
5,300 $6,000
Q4 2022

Feb 13, 2023
SELL
$1.17 - $2.12 $936 - $1,696
-800 Reduced 18.6%
3,500 $5,000
Q1 2022

May 16, 2022
BUY
$1.31 - $2.02 $3,144 - $4,848
2,400 Added 126.32%
4,300 $7,000
Q4 2021

Feb 14, 2022
BUY
$1.39 - $2.3 $416 - $690
300 Added 18.75%
1,900 $3,000
Q2 2021

Aug 16, 2021
BUY
$2.6 - $4.64 $260 - $463
100 Added 6.67%
1,600 $4,000
Q1 2021

May 13, 2021
BUY
$2.32 - $4.11 $1,160 - $2,055
500 Added 50.0%
1,500 $6,000
Q4 2020

Feb 09, 2021
SELL
$1.71 - $4.03 $1,710 - $4,030
-1,000 Reduced 50.0%
1,000 $2,000
Q3 2020

Nov 05, 2020
SELL
$1.58 - $2.15 $1,804 - $2,455
-1,142 Reduced 36.35%
2,000 $3,000
Q1 2020

May 14, 2020
BUY
$0.98 - $4.28 $3,079 - $13,447
3,142 New
3,142 $4,000

Others Institutions Holding ONCY

# of Institutions
43
Shares Held
1.31M
Call Options Held
0
Put Options Held
0
View Full List

About ONCOLYTICS BIOTECH INC

ONCY Quotes by TradingView
  • Ticker ONCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 57,867,400
  • Market Cap $51.5M
  • Description
  • Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...
More about ONCY
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email